Dupilumab improves pediatric type 2 asthma outcomes independent of patient baseline characteristics

This is the authors' abstract. We don't add key points for this paper.

Dupilumab, a biological therapy that blocks the shared receptor component for interleukins-4/13, reduced exacerbations and improved lung function in children with uncontrolled moderate-to-severe type 2 asthma independent of most baseline patient and asthma characteristics.